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Background: The introduction of antiretroviral therapy in 1996 improved the longevity and wellbeing of peoples
living with HIV in the industrialized world including children. This survival benefit of antiretroviral therapy (ART) in
reducing HIV related deaths has been well studied in the developed world. In resource-poor settings, where such
treatment was started recently, there is inadequate information about impact of ART on the survival of patients
especially in children. So, this study aims to investigate predictors of mortality of children on ART. Therefore, the
objective of this study was to identify predictors of mortality among children on HAART.
Methods: A retrospective cohort study was conducted on 432 children who initiated antiretroviral therapy from
June 2006 to June 2011 at pediatrics ART clinic in Mekelle Hospital, Northern-Ethiopia. Data were extracted from
electronic and paper based medical records database and analyzed using Kaplan Meier survival and Cox proportional
hazard model to identify independent predictors of children’s mortality on ART.
Results: The total time contributed by the study participants were 14,235 child-months with median follow up of
36 months. The mortality rate of this cohort was 1.40 deaths per 1000 child-months or 16.85 deaths per 1000 child-years.
Age less than 18 months [ Adj.HR (95% CI) = (4.39(1.15-17.41)], CD4 percentage <10 [Adj.HR (95% CI) = 2.98(1.12-7.94)],
WHO clinical stage (III&IV) [Adj.HR (95% CI) = 4.457(1.01-19.66)], chronic diarrhea[Adj.HR (95% CI) = 4.637(1.50-14.31)] and
hemoglobin < 8 g/dl[Adj.HR (95% CI) = 3.77(1.29-10.98)] all at baseline were significantly and independently associated
with survival of children on ART.
Conclusions: Mortality of children on ART was low and factors that affect mortality of children on ART were age less than
18 months, lower CD4 percentage, advanced WHO clinical stage (III&IV), presence of chronic diarrhea and lower
hemoglobin level all at baseline. The high early mortality rate would support the value of an earlier treatment start before
development of signs of immunodeficiency syndrome despite the method of HIV diagnosis and WHO stage.
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The introduction of antiretroviral viral therapy (ART) in
1996 has improved survival and quality of HIV-infected
patients in the developed countries. This survival benefit
of highly active antiretroviral therapy (HAART) in redu-
cing HIV related deaths has been well studied in the
developed world. In resource-poor settings however, where
such treatment was started recently, knowledge on treat-
ment results is limited. Moreover, mortality has been high
in the first month of ART initiation. But factors con-
tributing to high mortality are poorly investigated [1-3].
About 1,400 children under the age of 15 are infected
with HIV every day and approximately 90% of these
infections occur in sub-Saharan Africa. Without appropri-
ate care and treatment, more than 50% of newly infected
children die before celebrating their second birthday [4-6].
The use of ART has dramatically reduced HIV-
associated mortality and morbidity among children in
resource-rich settings. Pediatric HIV has been transformed
from rapidly fatal infection of early childhood to a manage-
able chronic disease. For this reason, many HIV infected
children are aging into adolescence and early adulthood
[3-5]. But according to American Academy of Pediatrics,
there might be differences from country to country in
many ways such as nutritional status, racial or ethnic and
gender differences in total lymphocyte count and CD4+
cell count [6].
Findings from studies in Africa and other low income
countries also showed that there was good result of the
ART programs i.e. the mortality of children on ART has
decreased [7-10]. But in sub-Saharan Africa including
Ethiopia, there is substandard information about treat-
ment results and the impact of ART on mortality of
children. The independent predictors of survival among
children living with HIV and on ART remain poorly
characterized in Ethiopia. Therefore, the available evi-
dence in Ethiopia regarding the determinants of survival
among children less than 15 years old is inadequate. For
this reason, this study dares to investigate the predictors
of survival among under 15 year old children on ART.Methods
Study area and period
The study was conducted in Mekelle Hospital 783kms far
north of Addis Ababa. Mekelle Hospital serves as a referral
hospital for Tigray region and neighboring regions (Afar
and Amhara) with a catchment population of 8 million.
ART program was introduced in 2003 as fee service and
the free ART program started in March 2005. A total of
660 HIV infected children were enrolled and 510 of them
were started on ART since ART started in Mekelle Hos-
pital (June 2006-June 2011). Diagnosis of HIV in children
was done based on antibody test at 18 months of age.Records of children who start treatment between June
1, 2006 and may 31, 2011 were retrieved.
Study design and sampling
A retrospective cohort study was conducted among 432
records of under 15 years old children on ART. The
patients’ ART identification numbers were used to extract
the necessary information from the different ART record-
ing formats. Socio-demographic characteristics, baseline
clinical and laboratory measurement information, and
treatment outcomes were abstracted from patients’ cards
and database and the primary outcome measure was
patient mortality (Time death). Seventy eight Transferred
in children on ART were excluded because it was impos-
sible to get their baseline information.
Data collection and quality control
A standard checklist was used for recording information
extracted from database and patient cards. This form is
developed using the standardized ART entry and follow
up form employed by the ART clinic. The laboratory
results of CD4 count recorded before starting ART were
used as a baseline values. If there is no pre-treatment
laboratory test, however, results obtained within one
month of ART initiation were considered as baseline
values. Four experienced ART nurses who were trained
on comprehensive HIV care and involved in patient follow
ups collected the data and data collection was supervised
by two trained supervisors. During the data collection
process the filled checklist was checked for their com-
pleteness, consistency and accuracy by the principal in-
vestigator every day. Mode, median and mean values was
used to address incompleteness, inconsistencies and in-
accuracy depending on the measurement scale. The data
were entered and cleaned using SPSS version 16.0 by data
clerks and exported to STATA version 11.0 for analysis.
Statistical analysis
Descriptive statistics such as median, mean, standard
deviation and proportions were used to describe the
general characteristics of the cohort. Person-months/years
of follow up were calculated by assessing the date of
enrollment for ART and death or censoring. The role of
the variables on patient survival was analyzed using
Kaplan-Meier survival analysis method. Log Rank test
was used to test the equality of survival probabilities
and compared across the different groups of covariates.
The overall survival function and separate estimates for
the stratum of covariates were considered as statisti-
cally significant at p-value < 0.05 in the Log- rank test.
Hazard ratios (HR) with 95% confidence intervals were
used as effect measures. Multivariable Cox proportional
hazards regression was used to assess the effect of baseline
predictors on the survival of children on ART. Variables
Table 1 Base line socio-demographic and clinical
characteristics of children on ART, Mekelle, hospital, and
Northern Ethiopia
Baseline variables
Survival status, N = 416
Censored DEAD Total
N % N % N
Sex (N = 416)
Male 190 48.00 10 50.00 200 48.10
Female 206 52.00 10 50.00 216 51.90
Age at ART initiation (N = 416)
≥120 months 56 14.14 3 15.00 59 14.18
60-120 months 140 35.35 4 20.00 144 34.62
36-59 months 69 17.42 1 5.00 70 16.83
18-35 months 73 18.43 4 20.00 77 18.51
<18 months 58 14.65 8 40.00 66 15.87
Primary care giver (N = 402)
Parents 294 77.00 18 90.0 312 77.60
Relatives 66 17.30 1 5.00 67 16.70
Guardians & Orphan 22 5.80 1 5.00 23 5.70
Missing 14 3.36
TB at baseline (416)
Yes 112 28.30 15 75.00 127 30.53
No 284 71.72 5 25.00 289 69.47
Baseline WHO clinical stage (N = 416)
stage I & II 93 23.50 1 5.0 94 22.60
stage III 187 47.20 14 70.0 201 48.30
stage IV 116 29.30 5 25.0 121 29.10
CD4 percentage (N = 412)
≥10% 223 56.89 6 30 229 55.58
<10% 169 43.11 14 70 183 44.42
Hemoglobin level (N = 408)
≥8 g/dl 363 93.56 15 75 378 92.65
<8 g/dl 25 6.44 5 25 30 7.35
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ate analysis to estimate hazard ratios with 95% confidence
intervals for the mortality rate among children on ART
for the covariates at their ART initiation. Model adequacy
was assessed using Schoenfeld residuals [11].
Ethical considerations
Ethical clearance was obtained from the Institutional re-
view board (IRB) of Mekelle University. All information
collected from patients cards were kept strictly confiden-
tial and names of children or their parents were not in-
cluded in the abstracted data.
Results
Base line cohort characteristics
A total of 432 study participants (children under 15 years
old) were included in the study and 416 (96.3%) of the
432 records were included in the analysis. The sample
comprised 216 (53%) females and 200 (47%) males. The
ages of the cohort at ART initiation were relatively late
with median age of 53 months with IQR (24–96) months.
Clinically 405 (97.40%) of the children were started on
first line ART regimen while the rest started on second
line. During the ART initiation 54 (12.9%) of children
had tuberculosis out of these 2 were died. Additionally
236 (56.7%) had chronic diarrhea and 4 were died during
the follow up time (Table 1).
Survival pattern of the cohort
Out of the 416 cohort of children on ART, 313 (75.24%)
were alive, 20 (4.81%) had died, 23 (5.53%) lost to follow
up, and 60 (14.42%) were transferred out. After initiation
of ART, children were followed for a median survival of
36 months with IQR of 17 to 50 months and the cohort
contributed to a total of 14,235 person-months of follow
up. Mortality rate in this cohort was found to be 1.40
per 1000 child-months. Out of the 20 children who died,
11 [2.39 per 1000 child-months (95% CI, 1.33, 4.32)] died
within 12 months of ART initiation while 9 [ 0.93 per 1000
child-months (95% CI, 0.48, 1.79) ] died after 12 months
(Figure 1).
Predictors of mortality
In bivariate analysis, factors associated with mortality
were: Hgl level <= 8 g/dl, presence of chronic diarrheal
disease, CD4 percentage <10% at ART initiation, WHO
clinical stage (III&IV) and age less 18 months. Those pa-
tients who have Hgl level <=8 g/dl were four times more
likely to die than Hgl level > 8 g/dl at baseline (crude
hazard ratio(CHR)) [CHR (95% CI) = 3.77 (1.29,10.98)].
Patients who have chronic diarrheal disease during treat-
ment initiation were five times more likely to die com-
pared with those who have not [CHR (95% CI) = 4.64
(1.27,10.06)]. Those patients whose CD4 cell percentwas <= 10% was three times more likely to die than
those patients whose CD4 percent was greater than 10%
[CHR (95% CI) = 2.98 (1.12,7.94)]. Moreover, those
patients with WHO stage (III and IV) were nine times
more likely to die than patients on stage (I and II)
[CHR (95% CI) = 8.87(1.09,71.96) ].But In multivariate
analysis five baseline characteristics, Age < 18 months,
WHO clinical stage III and IV, presence of chronic
diarrhea, CD4 <= 10 percent and hemoglobin <8 gm/dl
were found to be the independent predictors of mortality
(Table 2).
Discussion
The findings of this study indicated that from the registered
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Figure 1 Overall Kaplan - Meier probability of survival curve with 95% confidence intervals of children on ART, Mekelle Hospital, and
Northern Ethiopia.
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of 16.85 deaths per 1000 child-years of death. About 23
(5.53%) patients were lost to follow up. Mortality was
higher in the first 12 months after ART initiation (2.39
death per 1000 child months) But the over all mortality
was 1.40 deaths per 1000 child-months. The over all
mortality rate was actually lower when compared with
two different studies done in Kenya which reported an
overall mortality of the cohort of children on ART as 47
and 84 deaths per 1000 child years [12,13].
Early mortality (death <18 months after ART initiation)
was higher than late mortality (death >= 18 months after
ART initiation) in this study. This finding is consistent
with a study done in USA and ten European countries
and South Africa which showed that most of the deaths
occurred in the first 6 months following ART initiation
[14-16]. Children in WHO clinical stage IV and with se-
vere immunodeficiency had a significant risk of early
death at 3 or 6 months [17-19]. This indicated that early
HIV diagnosis and early antiretroviral therapy might not
be well adopted as recommend which could have reduced
early infant mortality by 76% in this study [20,21].
Mortality rate among <= 18 months old children on
ART was 56.80 deaths per 1000 child years which was
higher as compared with the age 120 months or above
i.e. 16.06 deaths per 1000 child-years. This study was
in line with a study done in Zambia that showed, as
age increases mortality rate will decreased [22]. More-
over, a study done in Malawi ,South Africa and Demo-
cratic Republic Congo also revealed that younger age
(<18 months) and late WHO stage were more likely to
die [23-25]. However, this finding contrasts with studies
conducted in Uganda and Zambia that showed children
initiated ART at an older age were associated with higher
mortality [26,27].Children with hemoglobin level < 8 g/l were four times
more likely to die than those with ≥ 8 g/dl. When results
of this study was compared against a 4 years clinical
cohort study in Kenya and Zambia among <15 years
aged children, children with baseline hemoglobin level
of ≤ 8 g/l was two times more likely to die than children
with hemoglobin level >8 gm/dl [13,22].
Children who initiated ART at WHO clinical stage
(III/IV) were associated with higher mortality. Studies
done in South Africa pointed out that, advanced disease
(WHO stage III&IV) had an increased risk of mortality
[23,28]. Moreover, studies from Cote d’Ivoire, Malawi,
and Ethiopia stated that children with advanced HIV
disease and very low CD4% have been found to be at
highest risk of early mortality following HAART initi-
ation [18,29,30].
Hemoglobin level ≤ 8 gm/dl, CD4 count percent ≤50/ul
was found to be significant predictors. This is consistent
with studies conducted in Addis Ababa, Ethiopia at
Zewditu memorial hospital and All African Leprosy
and Rehabilitation Centre (ALERT hospital), showed that
severe wasting, severe immunodeficiency (absolute CD4)
and low hemoglobin value and, lower age and immuno-
suppression (low CD4 count) were associated with mor-
tality [31,32].
The sensitivity analysis was performed including the
composite endpoint of lost to follow-up (LTFU) and
death. The proportion of the lost to follow-up included
as being dead were 10.34% (3.02 per 1000 child-months)
almost doubled the mortality rate. Age less than 18 months,
hemoglobin level, CD4 < 10%, were significantly associated
with death. Similar study conducted in South Africa dis-
played that age less than 18 months, CD4 < 10% ,weight for
age Z-score, and female gender were significantly associated
with mortality [16]. A study from ten treatment programs
Table 2 Predictors of mortality among a sample of HIV
infected cohorts of children on anti-retroviral treatment
in Mekelle hospital, Northern Ethiopia
Variables P-value HR [95% CI]
Age in months at ART initiation
≥120 1.00
60-120 0.365 0.499 0.111 2.248
36-59 0.305 0.303 0.031 2.963
18-35 0.941 0.943 0.201 4.433
<18 0.036 4.387 1.150 17.410
Gender 1.00




Yes 0.864 1.143 0.248 5.276
Primary care giver
Parents 1.00
Relatives 0.132 0.209 0.027 1.605
Guardian/orphan 0.343 0.329 0.033 3.271
Chronic Diarrhea
No 1.00 1.00
Yes 0.008 4.637 1.502 14.314
Hemoglobin level
≥8 g/dl
<8 g/dl 0.015 3.769 1.294 10.979
CD4 percentage
≥10% 1.00
<10% 0.029 2.976 1.115 7.944
WHO clinical stage
Stage I & II 1.00
Stage III & IV 0.048 4.457 1.010 19.664
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Zimbabwe) showed that ignoring LTFU led to substantial
underestimation of mortality [33]. Finally data on conri-
moxazol prophylaxis was not collected in this study be-
cause it was started 3 years after the start date of this
study. But a study done among Zambian children on
ART reported that Daily cotrimoxazole prophylaxis has
been shown to substantially reduce non–Pneumocystis
jiroveci–related deaths and hospital admissions in chil-
dren after infancy, and it is a recommended standard of
care for all HIV-infected children. For this reason, this
study recommends a further study on added impact of
cotrimoxazole prophylaxis among children who are re-
ceiving ART [34].
The main weakness of the study is the composition of
the study participants with almost half of the childrenbeing 5 years or more. As the mortality of HIV infected
children is higher in lower age groups this may under-
estimate the estimates because many younger patients
with poor prognosis were probably not included as they
died early or were not linked to the program. Finally
retrospective cohort study design also limits our ability
to gather data about factors that may influence the risk
of mortality, for example factors such as lack of family
supports, cares given at family level etc.
Conclusion
In conclusion, findings of this study indicated that mor-
tality in this cohort was found to be 4.8% deaths or 1.40
per 1000 child-months on ART. Finally, age less than
18 months, WHO clinical stage III & IV, chronic diarrhea
and hemoglobin < 8 g/dl at baseline remained independ-
ent predictors of mortality. The high early mortality in the
present study would support the value of an earlier treat-
ment initiation before development of signs of immuno-
deficiency. Generally, it is sensible to give due emphasis
about comprehensive early HIV treatment, care and sup-
port for all children on ART to improve survival of chil-
dren on ART. Finally further study is needed about the
effect of cotrimoxazol prophylaxis on mortality of children
on ART.
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